StockDuty ← Dashboard Aug 07, 2026 08:51 AM ET
CatalystFDA/Bio

Revolution Q2 Net Loss Widens; Plans Phase 3 Study Of Elironrasib In Q4; Wedbush Lifts Price Target

Revolution Q2 Net Loss Widens; Plans Phase 3 Study Of Elironrasib In Q4; Wedbush Lifts Price Target

What changed
Revolution Q2 Net Loss Widens; Plans Phase 3 Study Of Elironrasib In Q4; Wedbush Lifts Price Target
Why it matters
Revolution Q2 Net Loss Widens; Plans Phase 3 Study Of Elironrasib In Q4; Wedbush Lifts Price Target — impact context not separately stored; see What changed.
Sources
eodhd
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA →